RenovoRx Inc (RNXT) - Total Assets
Based on the latest financial reports, RenovoRx Inc (RNXT) holds total assets worth $11.21 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RenovoRx Inc (RNXT) net assets for net asset value and shareholders' equity analysis.
RenovoRx Inc - Total Assets Trend (2019–2024)
This chart illustrates how RenovoRx Inc's total assets have evolved over time, based on quarterly financial data.
RenovoRx Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
RenovoRx Inc's total assets of $11.21 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.1% |
| Accounts Receivable | $43.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how RenovoRx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RNXT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RenovoRx Inc's current assets represent 96.4% of total assets in 2024, a decrease from 99.8% in 2019.
- Cash Position: Cash and equivalents constituted 88.1% of total assets in 2024, down from 92.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
RenovoRx Inc Competitors by Total Assets
Key competitors of RenovoRx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
RenovoRx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.83 | 5.66 | 0.47 |
| Quick Ratio | 5.68 | 5.66 | 0.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.10 Million | $8.26 Million | $-2.19 Million |
RenovoRx Inc - Advanced Valuation Insights
This section examines the relationship between RenovoRx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.49 |
| Latest Market Cap to Assets Ratio | 3.99 |
| Asset Growth Rate (YoY) | 453.8% |
| Total Assets | $8.12 Million |
| Market Capitalization | $32.36 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values RenovoRx Inc's assets at a significant premium (3.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: RenovoRx Inc's assets grew by 453.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for RenovoRx Inc (2019–2024)
The table below shows the annual total assets of RenovoRx Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.12 Million | +453.75% |
| 2023-12-31 | $1.47 Million | -79.82% |
| 2022-12-31 | $7.26 Million | -55.39% |
| 2021-12-31 | $16.29 Million | +750.94% |
| 2020-12-31 | $1.91 Million | -15.68% |
| 2019-12-31 | $2.27 Million | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was… Read more